Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate Vaccination

著者: Jayashankar, Lakshmi, Hafner, Richard
出版年 Front Immunol (2016)

Immune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis: An Opportunity to Apply Precision Medicine Innovations to Infectious...

著者: Mahon, Robert N., Hafner, Richard
出版年 Clin Infect Dis (2015)

Applying Precision Medicine and Immunotherapy Advances from Oncology to Host-Directed Therapies for Infectious Diseases

著者: Mahon, Robert N., Hafner, Richard
出版年 Front Immunol (2017)

Viewpoint: Challenges and Opportunities in Tuberculosis Research

著者: Kim, Peter S., Makhene, Mamodikoe, Sizemore, Christine, Hafner, Richard
出版事項 2012

TB and HIV Therapeutics: Pharmacology Research Priorities

著者: Dooley, Kelly E., Kim, Peter S., Williams, Sharon D., Hafner, Richard
出版事項 2012

Antigen Clearance during Treatment of Disseminated Histoplasmosis with Itraconazole versus Fluconazole in Patients with AIDS

著者: Wheat, L. Joseph, Connolly, Patricia, Haddad, Nicholas, Le Monte, Ann, Brizendine, Edward, Hafner, Richard
出版事項 2002

Eliminating Tuberculosis and Tuberculosis–HIV Co-Disease in the 21st Century: Key Perspectives, Controversies, Unresolved Issues, and Needs

著者: Zumla, Alimuddin, Atun, Rifat, Maeurer, Markus, Kim, Peter S., Jean-Philippe, Patrick, Hafner, Richard, Schito, Marco
出版事項 2012

Clearance of Fungal Burden during Treatment of Disseminated Histoplasmosis with Liposomal Amphotericin B versus Itraconazole

著者: Wheat, L. Joseph, Cloud, Gretchen, Johnson, Philip C., Connolly, Patricia, Goldman, Mitchell, Le Monte, Ann, Fuller, Deanna E., Davis, Thomas E., Hafner, Richard
出版事項 2001

Tolerance and Pharmacokinetic Interactions of Rifabutin and Azithromycin

著者: Hafner, Richard, Bethel, James, Standiford, Harold C., Follansbee, Stephen, Cohn, David L., Polk, Ronald E., Mole, Larry, Raasch, Ralph, Kumar, Princy, Mushatt, David, Drusano, George
出版事項 2001

Detection and Quantification of Differentially Culturable Tubercle Bacteria in Sputum from Patients with Tuberculosis

著者: Chengalroyen, Melissa D., Beukes, Germar M., Gordhan, Bhavna G., Streicher, Elizabeth M., Churchyard, Gavin, Hafner, Richard, Warren, Robin, Otwombe, Kennedy, Martinson, Neil, Kana, Bavesh D.
出版年 Am J Respir Crit Care Med (2016)

Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial

著者: Diacon, Andreas, Miyahara, Sachiko, Dawson, Rodney, Sun, Xin, Hogg, Evelyn, Donahue, Kathleen, Urbanowski, Michael, De Jager, Veronique, Fletcher, Courtney V., Hafner, Richard, Swindells, Susan, Bishai, William
出版年 Lancet Microbe (2020)

Tolerance and Pharmacokinetic Interactions of Rifabutin and Clarithromycin in Human Immunodeficiency Virus-Infected Volunteers

著者: Hafner, Richard, Bethel, James, Power, Maureen, Landry, Bernard, Banach, Mary, Mole, Larry, Standiford, Harold C., Follansbee, Stephen, Kumar, Princy, Raasch, Ralph, Cohn, David, Mushatt, David, Drusano, George
出版事項 1998

Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide

著者: Grosset, Jacques, Almeida, Deepak, Converse, Paul J., Tyagi, Sandeep, Li, Si-Yang, Ammerman, Nicole C., Pym, Alexander S., Wallengren, Kristina, Hafner, Richard, Lalloo, Umesh, Swindells, Susan, Bishai, William R.
出版事項 2012

The China tuberculosis clinical trials consortium network: a model for international TB clinical trials capacity building

著者: Liu, Yu-Hong, Chen, Shu, Gao, Jing-Tao, Zhang, Yao, Booher, Kimberly, Ding, Xiao-Fen, Shu, Wei, Du, Jian, Bao, Jing, Hafner, Richard, Hamilton, Carol D., Li, Liang
出版年 Infect Dis Poverty (2020)

Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy

著者: Brown, Ashley N., Drusano, George L., Adams, Jonathan R., Rodriquez, Jaime L., Jambunathan, Kalyani, Baluya, Dodge L., Brown, David L., Kwara, Awewura, Mirsalis, Jon C., Hafner, Richard, Louie, Arnold
出版年 mBio (2015)

Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical Trial

著者: Dooley, Kelly E., Miyahara, Sachiko, von Groote-Bidlingmaier, Florian, Sun, Xin, Hafner, Richard, Rosenkranz, Susan L., Ignatius, Elisa H., Nuermberger, Eric L., Moran, Laura, Donahue, Kathleen, Swindells, Susan, Vanker, Naadira
出版年 Am J Respir Crit Care Med (2020)

Tuberculous meningitis: a roadmap for advancing basic and translational research

著者: Jain, Sanjay K., Tobin, David M., Tucker, Elizabeth W., Venketaraman, Vishwanath, Ordonez, Alvaro A., Jayashankar, Lakshmi, Siddiqi, Omar K., Hammoud, Dima A., Prasadarao, Nemani V., Sandor, Matyas, Hafner, Richard, Fabry, Zsuzsanna
出版年 Nat Immunol (2018)

Novel Dosing Strategies Increase Exposures of the Potent Antituberculosis Drug Rifapentine but Are Poorly Tolerated in Healthy Volunteers

著者: Dooley, Kelly E., Savic, Radojka M., Park, Jeong-Gun, Cramer, Yoninah, Hafner, Richard, Hogg, Evelyn, Janik, Jennifer, Marzinke, Mark A., Patterson, Kristine, Benson, Constance A., Hovind, Laura, Dorman, Susan E., Haas, David W.
出版年 Antimicrob Agents Chemother (2015)

Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis

著者: Dooley, Kelly E., Miyahara, Sachiko, von Groote-Bidlingmaier, Florian, Sun, Xin, Hafner, Richard, Rosenkranz, Susan L., Ignatius, Elisa H., Nuermberger, Eric L., Moran, Laura, Donahue, Kathleen, Swindells, Susan, Vanker, Naadira, Diacon, Andreas H.
出版年 Am J Respir Crit Care Med (2020)

QT EFFECTS OF BEDAQUILINE, DELAMANID OR BOTH IN PATIENTS WITH RIFAMPICIN-RESISTANT-TB: A RANDOMIZED CONTROLLED TRIAL

著者: Dooley, Kelly E., Rosenkranz, Susan L., Conradie, Francesca, Moran, Laura, Hafner, Richard, von Groote-Bidlingmaier, Florian, Lama, Javier R., Shenje, Justin, De Los Rios, Jorge, Comins, Kyla, Morganroth, Joel, Diacon, Andreas, Cramer, Yoninah S., Donahue, Kathleen, Maartens, Gary
出版年 Lancet Infect Dis (2021)